Literature DB >> 31591672

Transparency in Health Economic Modeling: Options, Issues and Potential Solutions.

Eric Q Wu1, Zheng-Yi Zhou2, Jipan Xie3, Cinzia Metallo4, Praveen Thokala5.   

Abstract

Economic models are increasingly being used by health economists to assess the value of health technologies and inform healthcare decision making. However, most published economic models represent a kind of black box, with known inputs and outputs but undisclosed internal calculations and assumptions. This lack of transparency makes the evaluation of the model results challenging, complicates comparisons between models, and limits the reproducibility of the models. Here, we aim to provide an overview of the possible steps that could be undertaken to make economic models more transparent and encourage model developers to share more detailed calculations and assumptions with their peers. Scenarios with different levels of transparency (i.e., how much information is disclosed) and reach of transparency (i.e., who has access to the disclosed information) are discussed, and five key concerns (copyrights, model misuse, confidential data, software, and time/resources) pertaining to model transparency are presented, along with possible solutions. While a shift toward open-source models is underway in health economics, as has happened before in other research fields, the challenges ahead should not be underestimated. Importantly, there is a pressing need to find an acceptable trade-off between the added value of model transparency and the time and resources needed to achieve such transparency. To this end, it will be crucial to set incentives at different stakeholder levels. Despite the many challenges, the many benefits of publicly sharing economic models make increased transparency a goal worth pursuing.

Year:  2019        PMID: 31591672     DOI: 10.1007/s40273-019-00842-0

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  16 in total

1.  Let cost effectiveness models be open to scrutiny.

Authors:  Chris Poole; Samir Agrawal; Craig J Currie
Journal:  BMJ       Date:  2007-10-13

2.  Data Authorship as an Incentive to Data Sharing.

Authors:  Barbara E Bierer; Mercè Crosas; Heather H Pierce
Journal:  N Engl J Med       Date:  2017-03-29       Impact factor: 91.245

3.  Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7.

Authors:  David M Eddy; William Hollingworth; J Jaime Caro; Joel Tsevat; Kathryn M McDonald; John B Wong
Journal:  Value Health       Date:  2012 Sep-Oct       Impact factor: 5.725

Review 4.  Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1.

Authors:  J Jaime Caro; Andrew H Briggs; Uwe Siebert; Karen M Kuntz
Journal:  Med Decis Making       Date:  2012 Sep-Oct       Impact factor: 2.583

5.  A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis.

Authors:  Devin Incerti; Jeffrey R Curtis; Jason Shafrin; Darius N Lakdawalla; Jeroen P Jansen
Journal:  Pharmacoeconomics       Date:  2019-06       Impact factor: 4.981

6.  Can Economic Model Transparency Improve Provider Interpretation of Cost-effectiveness Analysis? Evaluating Tradeoffs Presented by the Second Panel on Cost-effectiveness in Health and Medicine.

Authors:  William V Padula; Robert Brett McQueen; Peter J Pronovost
Journal:  Med Care       Date:  2017-11       Impact factor: 2.983

7.  Finding Resolution for the Responsible Transparency of Economic Models in Health and Medicine.

Authors:  William V Padula; Robert Brett McQueen; Peter J Pronovost
Journal:  Med Care       Date:  2017-11       Impact factor: 2.983

8.  Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors.

Authors:  Darren B Taichman; Peush Sahni; Anja Pinborg; Larry Peiperl; Christine Laine; Astrid James; Sung-Tae Hong; Abraham Haileamlak; Laragh Gollogly; Fiona Godlee; Frank A Frizelle; Fernando Florenzano; Jeffrey M Drazen; Howard Bauchner; Christopher Baethge; Joyce Backus
Journal:  JAMA       Date:  2017-06-27       Impact factor: 56.272

Review 9.  Economic evaluation in chronic pain: a systematic review and de novo flexible economic model.

Authors:  W Sullivan; M Hirst; S Beard; D Gladwell; F Fagnani; J López Bastida; C Phillips; W C N Dunlop
Journal:  Eur J Health Econ       Date:  2015-09-16

10.  Benefits, Challenges and Potential Strategies of Open Source Health Economic Models.

Authors:  William C N Dunlop; Nicola Mason; James Kenworthy; Ron L Akehurst
Journal:  Pharmacoeconomics       Date:  2017-01       Impact factor: 4.981

View more
  6 in total

1.  Improving Transparency in Decision Models: Current Issues and Potential Solutions.

Authors:  Paul Tappenden; J Jaime Caro
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

Review 2.  Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness.

Authors:  Clara Marquina; Ella Zomer; Sandra Vargas-Torres; Sophia Zoungas; Richard Ofori-Asenso; Danny Liew; Zanfina Ademi
Journal:  Pharmacoeconomics       Date:  2020-10       Impact factor: 4.981

3.  Putting Stakeholder Engagement at the Center of Health Economic Modeling for Health Technology Assessment in the United States.

Authors:  Richard Z Xie; Erica deFur Malik; Mark T Linthicum; Jennifer L Bright
Journal:  Pharmacoeconomics       Date:  2021-05-13       Impact factor: 4.981

4.  Development of a pharmacoeconomic registry: an example using hormonal contraceptives.

Authors:  Annesha White; Meenakshi Srinivasan; La Marcus Wingate; Samuel Peasah; Marc Fleming
Journal:  Health Econ Rev       Date:  2021-03-20

5.  Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review and meta-analysis of cost-utility studies.

Authors:  Akhil Sasidharan; Bhavani Shankara Bagepally; S Sajith Kumar; Kayala Venkata Jagadeesh; Meenakumari Natarajan
Journal:  PLoS One       Date:  2022-06-16       Impact factor: 3.752

Review 6.  A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.

Authors:  Wei Gao; Dominic Muston; Matthew Monberg; Kimmie McLaurin; Robert Hettle; Elizabeth Szamreta; Elyse Swallow; Su Zhang; Iden Kalemaj; James Signorovitch; R Brett McQueen
Journal:  Pharmacoeconomics       Date:  2020-11       Impact factor: 4.981

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.